Author Archives: admin


Kate and Flash riding high following injuries recovery – The Scarborough News

Katie Brickman and Flash both recovered from shocking injuries. Photo by Tony Bartholomew.

But vet Katie Brickman, from Welburn, near Malton, refused to give up when doctors told her a hand injury had ended her riding career.

She used the he same determination to bring her horse, Flash, back from an injury most competition horses would never recover from.

Katie, 29, who works at Minster Equine Veterinary Clinic in Ripon, suffered an horrific injury in March 2017 when she fell over while carrying a glass bottle of antibiotics, severing an artery in her left hand.

She was rushed to hospital in Hull, where she underwent two operations, but was told the damage was so serious, she would never be able to properly grip reins again and was advised to retire from riding.

Two months later, Katie suffered another devastating blow when Flash, her competition horse, suffered a serious injury when he ripped a ligament in his stifle joint at the top of his leg while in his field.

Flash was left critically lame by an injury that was so serious, he had to remain on box rest [confined to stable] for six months, and the prognosis was so bleak, he would have to be retired.

Katie and Flash have confounded expectations by making a miracle recovery and returned to competition this year in the world of eventing. Not only have they enjoyed their best-ever year with four wins, they have qualified for Badminton Grassroots Championships at one of the biggest events in the world equine sporting calendar.

Katie, who has been a vet with Minster Equine Veterinary Clinic at Ripon, York and Malton for six years, said: Flash and I have both gone from being told neither of us will never compete again to qualifying for Badminton Grassroots Championships. He has had an amazing season and its been our best ever year.

It goes to show you should never give up and all horses deserve a chance to recover from even the worst kind of injuries. I never gave up hope for either of us, but to reach Badminton is beyond my wildest dreams.

Flash is a very special horse because he had a tough start as I dont think he was treated well before I got him so hes very nervous.

It was really grim news about his injury as he as extremely lame, but I was determined to do everything to help him recover even though everything was stacked against him.

Katie still recovering from the severed artery, which left her hand in a bandage and cast, when Flash, a nine-year-old black Irish Sports Horse, suffered a freak injury in his field.

After six months of box rest, Katie took him for a bone scan at Rainbow Equine Hospital.

While she feared he would never compete in eventing again, she hoped Flash could at least be a pleasure hack.

As an experienced vet, she started giving him laser, shockwave and ultrasound treatment to the injured stifle joint, as well as stem cell therapy.

By August 2018, he was making such good progress, Katie decided to test out his recovery, as well as her own, by jumping and then this year started competing.

In October 2018, she competed at Askham Bryan College in York and won.

Go here to see the original:
Kate and Flash riding high following injuries recovery - The Scarborough News

I thought I had glandular fever on my gap year, but it turned out to be leukaemia – Telegraph.co.uk

It was meant to be the start of Tom Hunts gap year a fortnight in eastern Europe with five school friends. He had achieved an A* and two As in his A-levels and had an offer to study medicine at the University of Manchester. Before then, he wanted to do a ski season and travel around south-east Asia. But a week into his holiday, at the beginning of September last year, Tom was so ill he couldnt eat, drink or get out of bed. He booked a flight home from Prague.

When I picked him up from the airport, he looked dead, says Andrea, 51, his mother. He was really grey and smelt of bacteria.

Toms symptoms loss of appetite, fatigue, dizzy spells had all the hallmarks of glandular fever. But he also had a large, swollen haematoma on his knee, which had appeared after hours spent with his legs crossed on a train.

When I woke, it was killing me, just here, says Tom, 19, pointing at his thigh above his left knee. I thought it was a dead leg, but there was a massive lump and it was painful to walk.

Andrea thought Tom would get better with rest but within a week, having returned to the family home, he was hospitalised. The GP told Andrea: This lad needs tests and monitoring,because hes at risk of infection.

Read the original post:
I thought I had glandular fever on my gap year, but it turned out to be leukaemia - Telegraph.co.uk

Global Joint Pain Injections Market Growth Rate, Production Volume and Future Opportunities From 2019-2028 – Trade Examiner

A Recent Research By MarketResearch.Biz OnJoint Pain Injections MarketProvides A Professional, In-depth, Comprehensive, and Well-designed Insights that can help you to make better business decisions

The global Joint Pain Injections Market is studied and analyzed with the help of a complete primary and secondary market research. The report provides broad industry data on the Joint Pain Injections market, such as size, forecasted growth, profitability, key players, market share and market trends will give you a high-level overview of Joint Pain Injections market opportunities. This report studies the global market size of Joint Pain Injections, especially focuses on the key regions like North America, Europe and Asia-Pacific, South America, Middle East, and Africa

The market size section gives the Joint Pain Injections market revenues, covering historic growth of the market as well as forecasting the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others.

For Better UnderstandingThe Complete Report Through TOC, Figures, and Tables Get Free Sample Copy (Download PDF) @https://marketresearch.biz/report/joint-pain-injections-market/request-sample

List of key players profiled in the Joint Pain Injectionsmarket research report: which is very important for the manufacturers.

Allergan Plc., Pfizer Inc, Sanofi, Anika Therapeutics Inc, Ferring B.V., Bioventus LLC, Flexion Therapeutics Inc, Zimmer Biomet Holdings Inc, Seikagaku Corporation, Chugai Pharmaceutical Co Ltd

The Joint Pain Injections Market report also covers segment analysis, including injection type, joint type, end-user, and region etc. cover different segment market size, both volume and value.

Segmentation by Injection type:

Corticosteroid InjectionsHyaluronic Acid InjectionsOthers (include, Platelet-rich plasma (PRP), Placental tissue matrix (PTM), etc.)Segmentation by joint type:

Knee & AnkleHip JointShoulder & ElbowFacet Joints of the SpineOthers (include, Ball and socket, etc.)Segmentation by end-user:

Hospital PharmaciesRetail PharmaciesOnline Pharmacies

Key market insights thoroughly study in this comprehensive report:

1. The analysis of Joint Pain Injections market provides market size and growth rate for the forecast period 2019-2028.

2. It offers comprehensive insights into the latest trends, trend forecast, and growth factors about the Joint Pain Injections market.

3. The report provides the latest analysis of market share, investment opportunities, growth drivers, and challenges.

4. It offers a complete overview of market segments and the regional outlook of Joint Pain Injections market.

5. The report offers a detailed overview of the competitive analysis, vendor landscape, and key market strategies to gain a competitive advantage.

Inquire/Speak To Expert for Further Detailed Information About Joint Pain Injections Report:https://marketresearch.biz/report/joint-pain-injections-market/#inquiry

Worldwide research for Joint Pain Injections Industry Report examines the Below Topics:

01: Joint Pain Injections Market Overview.

02: Global Joint Pain Injections Industry outlook, revenue (USD$) and Market Size by Key application.

03: Joint Pain Injections Market distribution, Revenue (USD$) by country and region wise there Segments.

04: Global Joint Pain Injections industry market research Study.

05: Joint Pain Injections manufacturing Cost Study.

06: Joint Pain Injections value Chain and Revenue Study.

07: Joint Pain Injections Marketing research, conclusion, Study on buying and sales process.

08: Joint Pain Injections report regulatory system and installation.

09: Overall perspective for Joint Pain Injections report.

Browse CompleteTOC ofJoint Pain Injections Market@https://marketresearch.biz/report/joint-pain-injections-market/#toc

Get in touch with Us:

Mr. Benni Johnson ([emailprotected])

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Website:https://marketresearch.biz

View post:
Global Joint Pain Injections Market Growth Rate, Production Volume and Future Opportunities From 2019-2028 - Trade Examiner

For veterans, theres no better cause to push than helping other vets – Snoqualmie Valley Record

Two veterans in East King County are just two of many working to help other veterans.

North Bend veteran Jim Curtis doesnt mince words. If he supports something, youll know it.

The same can be said about things hes not a fan of. Hes vocal about his disdain for President Donald Trump and his actions while in office. And politicians, in general, who use veterans as a means for election.

Politicians use us to get elected or re-elected, Curtis said. But after they accomplish that goal, its sayonara until its time for campaigning again.

He channels his ideas through poetry. Mostly, he pours the passion into helping other veterans.

The cause that had his attention on Oct. 24 was this years Mother Brundage Memorial Raffle. He was raising funds for the family of Andrew Yoder, a U.S. Marine Corps combat veteran who was killed when a crane crashed down in Seattle last spring. The raffle would happen a few weeks later, on Nov. 10, the Marine Corps birthday.

Curtis sold tickets for $5 at the North Bend QFC and Mount Si Sports and Fitness. Even as he traveled south to the American Lake VA Medical Center in his red, 2011 Ford Ranger truck, he pushed for others to purchase raffle tickets.

When he approached the check-in desk, after briefly responding to a question prompted by the man at the counter, he popped his own.

Were doing this raffle, he often began his pitch. Curtis would often end his interactions with the words Semper Fi, the Marine Corps motto and short for semper fidelis a Latin phrase that translates to mean always faithful.

Semper Fi, hed say before leaving.

He used similar words each time, having memorized the phrases he echoed to try and convince the listener on the importance of the raffle. And, of course, to shell out some cash to help.

But what could one expect? When it came to serving especially when Curtis did, during the highly-controversial Vietnam War it was other veterans who understood. And it was other veterans who offered their support. Even if that support meant hanging flyers in a VA hospital nearly 55 miles south from Curtiss North Bend home. Or when it meant reaching out to politicians again. And again. And again.

Other causes

Before he began fundraising for Yoders family, Curtis was busy commuting south to Olympia, where he testified before state House and Senate committees. He thought Purple Heart license plates, those given to wounded military or family of those killed in action, should be issued free of payment of any fees or taxes. He had his own Purple Heart, after shrapnel from a mortar blast flew into his back, legs and derriere. This happened in 1969, during his first year in Vietnam, where he was a machine gunner.

Curtis presented the idea to Democrat Paul Graves, at the time house representative for District 5. When Lisa Callan was elected into the seat in November 2018, after defeating Graves by more than 3,000 votes, she approached him on his idea. She had met him previously while doorbelling in the area.

(The change) was the very least of what we could do to say Thank you, Callan said by phone, on Veterans Day. It gives veterans a way to share their story by even having that plate We need to do so much more for those who receive the Purple Heart and their families.

Curtis has other causes now. Hes invited Rep. Callan to visit the VA hospital he visits regularly, to see the condition of the buildings and to hopefully get some kind of change. The facilities are in a degraded state, compared to the state of medical buildings elsewhere, Curtis said. The walls have dark scuff marks, in some spots reaching about a foot in height. And for veterans, who sacrificed their time and had their lives on the line, it just wasnt up to par. Callan hasnt yet paid a visit to the hospital, but said that was in the works.

His other effort entails getting Gregory Pappy Boyingtons name recognized somewhere along the Medal of Honor Memorial Highway. Boyington was a graduate of Lincoln High School in Tacoma and an American combat pilot.He received the honor, the highest and most prestigious, after he spent months shy of two years in a Japanese prison camp.

There are plaques honoring vets there, but no Pappy in sight, Curtis said.

For another veteran, Curtis is simply looking for answers on why stem cell therapy is given to active-duty military at the Walter Reed National Military Medical Center in Bethesda, Maryland, and not an option for a disabled veteran Curtis knows in North Bend. The center serves military beneficiaries in the Washington, D.C. area as well as those from across the country and around the globe, according to its website.

He has contacted Congresswoman Kim Schrier about the issue, but has so far been having back-and-forth conversations with her staff via email, staff who, Curtis said, say shes too busy to leave her office. He figured the doctor he knocked on doors for, who at some point worked at Virginia Mason Medical Center in Issaquah, would be willing to make the drive, considering its not that far a commute, he said. Schrier did not return a request for comment by press deadline.

Gorman

But its not only Curtis helping other veterans. Marine veteran and Redmond resident Mark Gorman has been working to locate safe spaces for veterans without homes to sleep. He started the effort in 2004, when he owned a shop in Kingston. Everyday he spotted an older man fishing. And after that first initial contact, he struck up a friendship with the homeless man.

At one point, he just wasnt there fishing anymore, Gorman said. Three and four weeks went by, and Gorman decided to find the mans hide the safe spot he had carved out for himself outdoors. This guys all alone, no family. He died on his own of malnutrition and his heart gave up.

In the U.S., on a single night in January 2018, there were more than 37,800 veterans experiencing homelessness, according to the U.S. Department of Veteran Affairs. Of that number on that same night, about 23,300 were living unsheltered. Although there was a 5.4 percent decrease from the previous year, in the estimated number derived from the point-in-time count, Gorman said theres still a need.

When he moved to the Eastside in 2013, he realized there was an even bigger need locally. He began to help veterans, who for different, complex reasons, had lost their housing. Some he could help. Others, he said, werent mentally ready for the world.

They camp out in tents, others in trailers, some sleep in cars in church parking lots. Others sleep in Gormans backyard.

Three things in life we do as veterans sacrifice, duty and selflessness, Gorman said of his reasoning for helping. If those three things are not instilled in a boy as a young man, he will never become a real man. A man sacrifices for not only family and self but also for others around him.

Someday

While at the VA that cloudy afternoon in October, Curtis struck up a conversation with a gentleman who was also pushing his own cause to help veterans. He had acquired small American flags from another, and pinned one to Curtiss lapel, on the opposite side of where his Purple Heart medal pin sat. In exchange, Curtis offered a poem he wrote for sergeant first class Nathan Chapman, the first soldier killed during the war in Afghanistan. He was from Puyallup.

Someday well talk about this war, just like those weve had before, was one line he recited in the waiting room. And the spectator, in response, cried. The two shook hands and bonded over the shared experience of serving the country.

Curtis turned to walk away, but not before saying Semper Fi.

After a quick chat in the waiting room of the American Lake VA Medical Center, Jim Curtis, right, is given a small American flag pin by a fellow veteran. Curtis was there drawing attention to his fundraising efforts. Staff photos / Ashley Hiruko

A sign hangs on the bulletin board at the VA medical center for the Ocean Warriors Birthday Party. Curtis hung others, like these, in areas with many eyes to see.

On a foggy October morning, Curtis drives south toward the Tacoma area. He had his flyers in hand, and raffle tickets to sell. They would benefit the family of Andrew Yoder, a Marine Veteran who died in Seattle during the crane collapse this spring. Staff photo/Ashley Hiruko

Read more from the original source:
For veterans, theres no better cause to push than helping other vets - Snoqualmie Valley Record

What to Know in Washington: Trump Ally in Impeachment Spotlight – Bloomberg Government

After weeks of Republican complaints that the Democrats impeachment inquiry relied on secondhand information, the centerpiece of this weeks public hearings is testimony from a man with a direct line to President Donald Trump.

The political peril for Trump, who was dealt a series of setbacks last week, will be heightened as the House investigation accelerates with three days of public hearings starting tomorrow.

No witness is more central than Gordon Sondland, the U.S. ambassador to the European Union, a Trump donor and a confederate with Rudy Giuliani in back-channel diplomatic efforts for the president in Ukraine.

Sondland, scheduled to testify Wednesday, has already amended his previous closed-door testimony once because of discrepancies with other witnesses. And now there will be new questions for him to answer about Trumps pressure on the government in Kyiv to launch a probe entangling former Vice President Joe Biden and other political foes of the president.

David Holmes, a member of the embassy staff in Kyiv, came forward last week to tell impeachment investigators that following a phone conversation between Sondland and Trump, the EU envoy told him the president didnt give a s about Ukraine and that the president only cares about the big stuff that benefits him like the Biden investigation that Giuliani, Trumps personal lawyer, was promoting.

Testimony from Tuesday through Thursday will come from a disparate cast of witnesses, some of whom could prove pivotal to the impeachment inquiry, including officials from the State Department, the White House national security teams, and Vice President Mike Pences office. Read more from Ryan Teague Beckwith and Billy House.

Former Adviser SaysAid Was Tied to Probe: A former top White House adviser told House impeachment investigators Ukrainians were advised Sept. 1 that U.S. military aid was being withheld until their president announced an investigation of a company that had hired Bidens son, Hunter. Tim Morrison, a former senior director of European and Russian affairs at the National Security Council, said Sondland told him how he had informed a high-ranking Ukrainian official that release of $400 million in aid was being linked to the investigations, according to a transcript of his closed-door testimony released Saturday.

The House committee also released testimony from Jennifer Williams, an aide to Vice President Mike Pence, who said she found some of the discussion on the July 25 call between the two leaders to be unusual and inappropriate. Read more from Billy House.

Funding Deadline: Lawmakers are facing a deadline of Thursday to pass legislation to continue funding the government, before they depart for a recess through the week of Thanksgiving. House and Senate leadership have expressed optimism that both chambers will pass a measure ahead of the deadline, though no continuing resolution has been introduced as of this morning and the House schedule offered few details of the timing of a vote.

I hope we pass the CR, House Majority Leader Steny Hoyer (D-Md.) said on the floor Friday. I hope its as clean as it can be. The measure will contain some usual anomalies, noncontroversial changes in funding levels or legislative language, Hoyer said.

FDA Pick to Face Questions on Frankenfish, Stem Cells, Vaping: Trumps selection to be the next head of the FDA will face a barrage of questions this week about his views on vaping, oversight of stem-cell therapies and even Frankenfish. Stephen Hahn, chief medical executive of the prestigious MD Anderson Cancer Center at the University of Texas in Houston, will go before the Senate Health, Education, Labor and Pensions Committee Wednesday for his first public hearing since being nominated to become commissioner of the Food and Drug Administration. Alex Ruoff details what to expect.

Risch Warns Erdogan of Sanctions: Senate Foreign Relations Chairman Jim Risch (R-Idaho) warned that if Turkish President Recep Tayyip Erdogan persists in the deployment of a Russian air defense system, he will move ahead with a sanctions bill. It is his choice, and he knows the consequences, Risch said in a statement on Friday evening. Just a day earlier, Risch had said that the Senate should hold off on sanctions over Turkeys invasion of Syria if Erdogan agreed to give up the S-400 anti-aircraft missile system. Read more from John Harney.

Anti-Robocall Agreement Reached: House and Senate negotiators on Friday reached an agreement on bipartisan legislation to combat illegal robocalls, and anticipate a vote on the measure this year. The House and Senate passed separate legislation earlier this year with broad bipartisan support, and staff has been working since August to reach an agreement on provisions from the two anti-robocall bills. Read more from Rebecca Kern.

Democrats Subpoena EPA Over Formaldehyde Analysis: Rep. Eddie Bernice Johnson (D-Texas), chairwoman of the House Science, Space, and Technology Committee, sent two subpoenas to the EPA Friday over the agencys alleged refusal to provide answers about removing formaldehyde from its review program outlook. Johnson said in an accompanying letter to EPA Administrator Andrew Wheeler that the committee had suffered through eight months of delayed and insufficient responses. The subpoenas were sent to Wheeler and David Dunlap, deputy assistant administrator for the agencys Office of Research and Development. Read more from Stephen Lee.

Democrats Use Super-PACs to Combat Trump: Wealthy Democratic donors are pouring money into outside groups as part of their effort to defeat Trump in 2020, avoiding contributions to a party apparatus that lost in 2016 and to leading candidates who dont want their help. Outside groups aligned with Democrats have pledged to spend more than $300 million attacking Trump, far more than the $67 million raised by the Democratic National Committee. With little primary opposition, Trump and the Republican Party are already in general election mode, free to spend millions in states hell need to win a second term. The Democratic groups are being fueled by seven-figure checks necessary to advertise in battleground states, blunting Trumps big campaign cash advantage. Read more from Bill Allison.

Buttigieg Wants Public College Free for Some: Pete Buttigieg called for spending $120 billion on the Pell Grant program and making public colleges tuition-free for students eligible for those federal grants as part of his proposal released Monday to improve college affordability. Unlike some of his primary opponents, Buttigieg isnt calling for public colleges to be tuition-free for all students, or for total student-debt cancellation. Hes said families that make over a certain income threshold should pay at least some of the cost of their kids higher education. The plan released Monday focuses on helping lower- and middle-income families. Read more from Tyler Pager.

Louisiana Governors Re-election May Offer Lessons for 2020: John Bel Edwards proved its possible to buck Trumps popularity, winning a second term to remain the only Democratic governor in the Deep South. His victory will give political strategists important insights on what it takes to motivate turnout going into 2020, said University of Pennsylvania political science professor Daniel J. Hopkins. Voters may feel more empowered to back a moderate Democrat, said Hopkins, who explores the nationalization of state politics in his book, The Increasingly United States.

In Louisiana, Trump headlined three rallies to try to drive turnout for Republican Eddie Rispone. Edwards, meanwhile, ran on a record of demonstrated independence from his national party. Read more from Jennifer Kay.

North Carolina Lawmakers Back New Congressional Map: North Carolina lawmakers have approved new congressional boundaries to be used in the 2020 elections. The 13 current U.S. House district lines were redrawn after a state court decided Oct. 28 that the map in place since 2016 couldnt be used, pending further review. The North Carolina Superior Court for Wake County had found that plaintiffs were likely to prevail in a lawsuit claiming the boundaries were illegally drawn to maximize Republican advantage. Read more from Andrew M. Ballard.

Barr Blasts Democrats: Attorney General William Barr fired a broadside against critics of Trump and congressional Democrats in particular while defending the presidents actions. In a fiery speech before the conservative Federalist Society on Friday, Barr said Trumps opponents are using every tool they can to intentionally sabotage his administration. Immediately after President Trump won election, opponents inaugurated what they called the Resistance, Barr said. They essentially see themselves as engaged in a war, to cripple by any means necessary, a duly elected government. Read more from Chris Strohm.

Trump, Kim at Odds Ahead of Deadline: The bonhomie between Trump and North Korean leader Kim Jong Un is nearing a key deadline showing new signs of strain. Trump urged Kim over the weekend to act quickly to get a nuclear deal done, suggesting the two leaders could meet again soon. His comments came hours after North Korea ruled out nuclear talks without a policy change by the U.S. and reported on a military drill observed by Kim himself.

Veteran North Korea nuclear adviser Kim Kye Gwan told Trump that Pyongyang will no longer give him things to boast about, the states official KCNA news agency today quoted him as saying. He added North Korea is no longer interested in talks that the U.S. uses to buy time. Read more from Glen Carey and Jihye Lee.

Lawmaker Speaks Out Against U.S. Defense-Cost Hike: Rep. Grace Meng (D-N.Y.) said Trump is destabilizing the U.S.s relationship with South Korea by demanding the Asian nation pay about $5 billion, or five times the amount of its current one-year deal, to host U.S. troops, Jihye Lee reports. Meng tweeted a letter Friday asking Defense Secretary Mark Esper and Secretary of State Michael Pompeo to devise a better strategy that values the alliance, adding that such a hike would be extorting South Korea. Meng said such a request also puts U.S. national security and economic interests in jeopardy. She asked the U.S. officials to reconsider and engage in good faith negotiations.

Esper Has Great Faith in U.S. Military Justice System: Secretary Esper expressed his faith in the countrys military justice system, after Trump last week pardoned two soldiers convicted in Afghanistan killings, Glen Carey reports. Id say first of all that we have a very effective military justice system, Esper said during a press conference at the Asean Defense Ministers Meeting-Plus in the Thai capital of Bangkok yesterday. U.S. military personnel are trained from day one about the laws of armed conflict and how to conduct themselves during wartime, he said.

China, U.S. Trade Talks Continue: Top negotiators from China and the U.S. talked again this weekend, after signs of concessions from both sides on some of the outstanding issues. Chinas Vice Premier Liu He, the countrys key negotiator in the trade talks with the U.S., spoke with Treasury Secretary Steven Mnuchin and Trade Representative Robert Lighthizer by phone on Saturday morning Beijing time, according to the Chinese Commerce Ministry. They had constructive discussions about each sides core concerns in the phase-one deal, and agreed to stay in close communication, the statement said. The USTR confirmed the call took place. Read more.

Trump to Tour Apples Austin Plant: President Donald Trump is scheduled to tour an Apple manufacturing plant in Austin, Texas, on Wednesday, the White House said yesterday. The president plans to visit the plant along with Apple CEO Tim Cook, according to a tweet by spokesman Judd Deere. The Austin American-Statesman newspaper reported that Trump will travel with Treasury Secretary Steven Mnuchin and other administration officials.

The company announced in September that its new Mac Pro computer will be assembled in Texas after it received exclusions from the Trump administration from tariffs on certain parts imported from China. The visit also comes at a time the U.S. and China are close to finalizing the first phase of a highly-anticipated trade deal. Read more from Hailey Waller.

Facebook, Google Donate Heavily to Privacy Advocacy Groups: Few companies have more riding on proposed privacy legislation than Google and Facebook. To try to steer the bill their way, the giant advertising technology companies spend millions of dollars to lobby each year, a fact confirmed by government filings. Not so well-documented is spending to support highly influential think tanks and public interest groups that are helping shape the privacy debate, ostensibly as independent observers.

Bloomberg Law examined seven prominent nonprofit think tanks that work on privacy issues that received a total of $1.5 million over an 18-month period ending Dec. 31, 2018. The groups included such organizations as the Center for Democracy and Technology, the Future of Privacy Forum and the Brookings Institution. The actual total is undoubtedly much higherexact totals for contributions were difficult to pin down. Read more from Daniel R. Stoller.

Scalia Says Big Law is Unwilling to Defend Conservative Views: Major law firms are shying away from defending conservative viewpoints in court, a trend that should trouble the legal profession, Labor Secretary Eugene Scalia told a group of right-leaning lawyers at a Federalist Society event on Friday. It is appropriate, admirable, and necessary for lawyers to take on clients and advance positions that may offend some observers, Scalia said. But some of the countrys biggest law firms appear to be disinclined to protect free speech and free trade in ideas, he argued, calling that evidence of a broad trend of conservative political views being under attack. Read more from Jaclyn Diaz.

To contact the reporters on this story: Zachary Sherwood in Washington at zsherwood@bgov.com; Brandon Lee in Washington at blee@bgov.com

To contact the editors responsible for this story: Giuseppe Macri at gmacri@bgov.com; Loren Duggan at lduggan@bgov.com

Excerpt from:
What to Know in Washington: Trump Ally in Impeachment Spotlight - Bloomberg Government

U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa – Ottawa Citizen

Just a few months after Health Canada began cracking down on private clinics offering unapproved stem cell therapies, at least one U.S. clinic has moved in to fill the vacuum with direct marketing to Canadian consumers.

The clinic from Burlington, Vermont, even offers shuttle buses to transport people from Ottawa to the clinic four hours away for treatment it suggests will end joint pain, among other things. Lunch and dinner are free, but each injection costs $6,880. Two for $10,880.

The treatments, using umbilical cord-derived mesenchymal stem cells, are not approved in either Canada or the United States. Health Canada warns that Canadians who travel abroad for stem cell treatments may put themselves at risk.

While stem cells, which were discovered at the University of Toronto in 1961 by James Till and Ernest McCulloch, promise to revolutionize many treatments and could offer breakthroughs for diseases, almost all are still considered experimental and have yet to be proven safe or effective. Clinical trials on numerous potential stem cell therapies are under way, including in Ottawa.

While research progresses, private stem cell clinics have popped up around the world making promises for treatments not yet proven safe or effective.

A 2018 study by Leigh Turner of the University of Minnesota Center for Bioethics found 43 clinics offering stem cell treatments in Canada and 750 in the U.S. Earlier this year, Health Canada sent Canadian clinics, including some in Ottawa, cease-and-desist letters.

Clinics in Vermont, near the Canadian border, appear to have ramped up marketing to Canadians since then. One clinic has been holding back-to-back seminars. Another says it stopped marketing in Canada after receiving a warning from Health Canada.

There have been cases of harm as a result of treatments, including two women who had permanent damage to their sight after stem cells were injected into their eyes at a Florida clinic. Other patients have been infected with unsterilized equipment and others have developed tumours at the site of stem cell injections.

A common harm, critics say, is exploitation.

Dr. Michael Rudnicki is director of the regenerative medicine program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute, says of stem cell therapy claims: If it sounds too good to be true, it probably is too good to be true.jpg

Health officials say the clinics are misusing the promise of stem cell therapy to exploit vulnerable patients.

These patients are in pain and they are suffering and they are looking for help and they are being exploited, said Dr. Michael Rudnicki, director of the regenerative medicine program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute.

If it sounds too good to be true, it probably is too good to be true.

At a recent seminar at a west-end Ottawa hotel meeting room, Roseanna Ammendolea of the Vermont Center for Regenerative Medicine told a packed room that her clinic and others like it had successfully treated people for pain related to arthritis, neuropathy and other ailments that affected joints using mesenchymal stem cells from umbilical cords. The stem cells, she claimed, are both effective and safe, saying there had been no issues with cell rejection.

We will not give injections if we feel that this injection will not be beneficial to our patients. This is why we are so successful.

Participants, including some who walked with canes and others who talked about being in pain and having mobility issues, were shown videos of people described as Canadian clients who claimed the treatments worked. One man said it was probably the best money I have spent in my life as far as my health. Another said she would do it again in a heartbeat and was able to do things she hadnt been able to do earlier.

They were also shown a slide showing long wait times for hip and knee replacements in Ontario, We are not a priority, she said. Where does that leave us? Participants werent told exactly how the stem cells were supposed to work, but claimed they had successfully improved pain and mobility issues in clients.

What the seminar goers werent told is that, even in the U.S., the treatment is not covered by health insurance because it remains unproven.

The U.S. Federal Drug Administration has issued a warning to consumers not to use cell therapies that are unapproved or unproven.

Stem cells have been called everything from cure-alls to miracle treatments. But dont believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware of potentially dangerous procedures and confirm whats really being offered before you consider anytreatment, the FDA said in a statement.

The only stem-cell-based products that are FDA-approved for use in the United States are blood-forming stem cells derived from cord blood for limited use in patients with disorders affecting the body system that is involved in the production of blood. Bone marrow is also used for these treatments, but is generally not regulated by the FDA for that use.

Health Canada has granted market authorization for a stem cell therapy to treat graft-versus-host disease and two cell-based gene therapies to treat certain cancers. Most cell therapies are still experimental.

I totally understand the skepticism of it, Doug Argento, who works at the Vermont Center for Regenerative Medicine, said in a telephone interview, but the fact is that things that are approved now and medically paid for were seen as renegade 20 or 30 years ago.

The treatment employs technology developed by Neil Riordan, founder, chairman and chief science officer of the Stem Cell Institute in Panama, using human umbilical cord tissue-derived mesenchymal stem cells. There are 41 such clinics across the U.S. Riordan also played a role in the development of a nutritional product called Stem-Kine, which producers claim without scientific backing increases the number of stem cells circulating in a persons body.

The stem cells injected in the clinic, Argento said, are from umbilical cord tissue as a result of caesarean births to reduce risk of infection.

Rudnicki, of The Ottawa Hospital Research Institute, says there is no evidence that these sorts of cells are regenerative at all. It would not pass muster in Canada.

The public has to understand that there are people out to remove them from their money.

Rudnicki says he regularly receives inquiries from people desperate to get stem cell treatments. He says he tries to connect them with clinical trials that they might be able to participate in.

Rudnicki noted there were multiple clinical trials in Canada, including treatments of autoimmune diseases, trials involving treatment for Type 1 diabetes and others.

But the use of these inappropriate cell types for treating arthritis and joints and so on is certainly not approved by Health Canada and would not be allowed in Canada under the regulations.

There is some evidence that injections of some stem cell products might have a temporary positive impact on inflammation, he said, but it will not be regenerative and will not restore function to joints. They are being sold a bill of goods.

Leigh Turner of the University of Minnesota Center for Bioethics, meanwhile, says the explosion in clinics offering unproven stem cell therapies in the U.S. is a marketplace that traffics in misrepresentation. It is easy to see how people are taken advantage of and scammed.

It is also difficult to find out about physical harms being done to patients.

There are no safety studies. We dont have good data. But we do know there have been some serious harms.

Stem cell therapies have the potential to become standard treatment in some areas, but they are not there yet, Turner said.

Businesses are tapping into genuine human suffering, desperation and also hope.

Turner also noted there was an excellent chance that the vials of liquid being injected into patients did not actually contain stem cells.

Dr. Jonathan Fenton of another stem cell clinic in Burlington, the Vermont Regenerative Medicine, said he had complained about the new clinic, the Vermont Center for Regenerative Medicine, which has a similar name and employs hard-sell tactics, he said.

His clinic takes bone marrow from patients hips and injects it. The procedure is done the same day. He says he regularly sees Canadian patients for bone marrow aspiration therapy and platelet-rich plasma treatments, using their own blood. The treatments, he says, speed healing and are allowed in the U.S. The use of bone marrow aspiration is neither proven nor allowed in Canada.

Fenton, who is secretary-treasurer of the American Academy of Orthopedic Medicine, acknowledged many people offering stem cell treatments are not doing it to the highest ethical standards.

He has filed complaints with state officials over clinics selling unsafe or fraudulent treatments. I have asked the state and federal judiciary to close down this clinic for committing fraud.

He said his platelet and bone marrow treatments were covered by a major Vermont health insurer because they saw the cost of benefits were going down and patients were requiring fewer surgeries.

He said he was told by Health Canada that he could not market in Canada. Representatives of the Vermont Center for Regenerative Medicine, meanwhile, said they had discussions with Health Canada about what they could and could not say when marketing in Canada before holding seminars in Ottawa and Halifax.

We have looked at the information provided and have not identified any immediate non-compliance with advertising regulations pertaining to Canadian health products, a Health Canada spokesperson said, adding that the agency was continuing to assess.

Back at a west-end Ottawa hotel, some participants in the seminar, including a retired pharmacist, said they were considering getting the treatments. But its expensive.

Another participant said he was skeptical. They seemed very sketchy when I went online.

epayne@postmedia.com

ALSO IN THE NEWS

Hoffman and Kaushic: Were losing the fight against superbugs

Super-agers, who live to at least 110, boast stronger immune systems, helping them fight off diseases

Spinal-cord stimulator really promising: Survivor moves legs for first time since Humboldt bus crash

More:
U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa - Ottawa Citizen

Hemophilia Treatment Market Dynamics, Pin-Point Analysis, Comprehensive Landscape, Demand Key Factors, Market Segments Regions, Therapy For Hemophilia…

(MENAFN - GetNews) Hemophilia Treatment Global Market Research Report: By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (Recombinant Coagulation Factor, Plasma-Derived Coagulation Factor, Desmopressin, Antifibrinolytic Agents), End User Global Forecast Till 2023

Hemophilia Treatment Market Overview

The global hemophilia market is forecasted to witness a steady growth of 6.10% during the forecast period between 2018 to 2023. The market valuation is slated to jump from USD 11,257.21 in 2017 to USD 16,059.17 by the end of the forecast period.

Request Free Sample Copy Available @ https://www.marketresearchfuture.com/sample_request/5688

The report published by Market Research Future (MRFR) identifies that the prevalence of hemophilia will spring up the demand for hemophilia treatment globally. The emergence of recombinant products for the treatment of hemophilia has blossomed the interest and demand for the market. The absence of a precise cure and the growing setbacks with the treatment of hemophilia has increased the need for discovering and coming up with new and effective solutions. Gene therapy is increasingly being explored and considered as a permanent solution for hemophilia and offers vast opportunities for the growth of the market.

However, the high cost associated with the treatment and the level of expenses required for consistent lab testing and imaging tests can go on to hamper the market growth of hemophilia treatment.

Hemophilia Treatment Market Segmentation

The global hemophilia treatment market segmentation is based in terms of type, end-user, and treatment.

By type, the market is categorized into hemophilia A, hemophilia B, and hemophilia C. The hemophilia A segment holds the largest share of the global market. The valuation of the segment is expected to reach USD 12.697.99 by the end of the forecast period, 2023. The calculated growth rate of the market annually has been projected to be 6.23% during the forecast period.

By treatment, the market comprises of recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, desmopressin, gene therapy, and antifibrinolytic agents. The recombinant coagulation factor concentrates is the largest market share holder with an expected CAGR of 7.01% during the review period.

By end-users, the market includes hospitals & clinics, research organization, and others. Hospitals & clinics lead this segmentation of the market and is valued at USD 7594.66 in 2017 and is expected to grow the fastest over the forthcoming years.

Hemophilia Treatment Market Regional Analysis

The regional segmentation of the hemophilia treatment market covers the following regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The Americas stand tall as the largest market share holder in the global geographical segmentation. This is due to the prevalence of the hemophilia disorder and the presence of a well-established healthcare sector. Growing expenditure in healthcare and increasing support for research and development activities are expected to aid the Americas region to maintain its leadership position. The North American market contributes more to the region than its southern counterpart.

Europe holds the second biggest market share due to a parallel growth pattern like the Americas. Moreover, government support for R & D activities for advanced medical therapies for hemophilia is another important driver to the market growth in this region.

Asia Pacific is expected to grow with the highest CAGR of 8.38% during the review period. The healthcare sector in this region is advancing at a rapid pace owing to the high disposable income in the region and expanding advanced medical facilities. The presence of a vast patient population base and a high healthcare expenditure is expected to positively impact the Asia Pacific market growth.

Hemophilia Treatment Market Competitive Landscape

The global hemophilia treatment market includes various noteworthy players like Baxter, F.Hoffmann-La Roche Ltd, Octapharma, Swedish Orphan Biovitrum AB, Pfizer Inc, CSL Behring, Sanofi, Kedrion, Novo Nordisk A/S, Bayer AG, Grifols International S.A, and Shire.

Feb 19th, 2019, Novo Nordisk announced in a press release about the US FDA approval of N8-GP, turoctocog alfa pegol, to help treat children and adults with hemophilia A in the United States. The therapy will be under the brand name of Esperoct

Feb 7th, 2019, Roche announced its joining with the World Federation of Hemophilia (WFH) Humanitarian Aid Program. The program will see the company treating more than 1,500 people with Hemophilia A across various developing countries.

Read Complete Report @ https://www.marketresearchfuture.com/reports/hemophilia-treatment-market-5688

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact Company Name: Market Research Future Contact Person: Abhishek Sawant Email: Send Email Phone: +1 646 845 9312 Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar City: Pune State: Maharashtra Country: India Website: https://www.marketresearchfuture.com/reports/hemophilia-treatment-market-5688

MENAFN1811201900703268ID1099290278

Read this article:
Hemophilia Treatment Market Dynamics, Pin-Point Analysis, Comprehensive Landscape, Demand Key Factors, Market Segments Regions, Therapy For Hemophilia...

WCM-Q explores law and ethics of stem cells and AI in medicine – The Peninsula Qatar

18 Nov 2019 - 8:02

Speakers at WCM-Qs Law and Medicine event taking part in a panel discussion on the law and ethics of stem cell science.

The legal and ethical implications of using stem cells and artificial intelligence (AI) in medicine were discussed at the latest instalment of Weill Cornell Medicine-Qatars (WCM-Q) Intersection of Law & Medicine series.Expert speakers at the event discussed the impact of recent advances in stem cell science and AI on the practice of medicine in Qatar and explored how new legal frameworks could be developed to protect the rights and safety of patients in the MENA region. The day-long event was organized by WCM-Q in collaboration with Hamad Bin Khalifa University and the University of Malaya of Kuala Lumpur, Malaysia.Stem cells are an exciting area for medical researchers because they have the potential to repair damaged or diseased tissues in people with conditions such as Parkinsons disease, type 1 diabetes, stroke, cancer, and Alzheimers disease, among many others. Stem cells can also be used by researchers to test new drugs for safety and effectiveness.WCM-Qs Dr. Amal Robay, WCM-Q assistant professor in genetic medicine and director of research compliance, said: Stem cells have the capacity for unlimited or prolonged self-renewal, and they can differentiate themselves into many different cell types to become tissue- or organ-specific cells with special functions. The central ethical dilemma of stem cell science arises from the fact that embryonic stem cells are derived from human embryos or by cloning, she explained.Visiting bioethics expert Dr. Jeremy Sugarman of Johns Hopkins University in Baltimore, US said that the public image of stem cell research had been damaged by a small number of high-profile cases in which scientists had behaved unethically. The field had also been hampered by different countries applying different laws to stem cell research, making international collaboration problematic, he said.Meanwhile, the use of AI in healthcare has the potential to leverage analysis of large amounts of data to improve patient outcomes, but poses ethical concerns regarding privacy, the diversity of data sources, biases and relying on non-human entities for potentially life-changing decisions.Dr. Barry Solaiman, assistant professor of law in the College of Law and Public Policy at HBKU said: Its very important that we bridge that gap between the professions of law and medicine, and that we understand the fundamental importance of ethicists to the advance of science. We need to consider how lawyers can help to develop laws to ensure that science advances and that it does so in ways that protect everyone involved.The event, which was co-directed by Dr. Solaiman and Dr. Thurayya Arayssi, professor of clinical medicine and senior associate dean for medical education and continuing professional development at WCM-Q, also featured other expert speakers.The event was accredited locally by the Qatar Council for Healthcare Practitioners-Accreditation Department (QCHP-AD) and internationally by the Accreditation Council for Continuing Medical Education (ACCME).

Follow this link:
WCM-Q explores law and ethics of stem cells and AI in medicine - The Peninsula Qatar

Qatar- WCM-Q explores law and ethics of stem cells and AI in medicine – MENAFN.COM

(MENAFN - The Peninsula) The legal and ethical implications of using stem cells and artificial intelligence (AI) in medicine were discussed at the latest instalment of Weill Cornell Medicine-Qatar's (WCM-Q) Intersection of Law & Medicine series.Expert speakers at the event discussed the impact of recent advances in stem cell science and AI on the practice of medicine in Qatar and explored how new legal frameworks could be developed to protect the rights and safety of patients in the MENA region. The day-long event was organized by WCM-Q in collaboration with Hamad Bin Khalifa University and the University of Malaya of Kuala Lumpur, Malaysia.Stem cells are an exciting area for medical researchers because they have the potential to repair damaged or diseased tissues in people with conditions such as Parkinson's disease, type 1 diabetes, stroke, cancer, and Alzheimer's disease, among many others. Stem cells can also be used by researchers to test new drugs for safety and effectiveness.WCM-Q's Dr. Amal Robay, WCM-Q assistant professor in genetic medicine and director of research compliance, said: 'Stem cells have the capacity for unlimited or prolonged self-renewal, and they can differentiate themselves into many different cell types to become tissue- or organ-specific cells with special functions. The central ethical dilemma of stem cell science arises from the fact that embryonic stem cells are derived from human embryos or by cloning, she explained.Visiting bioethics expert Dr. Jeremy Sugarman of Johns Hopkins University in Baltimore, US said that the public image of stem cell research had been damaged by a small number of high-profile cases in which scientists had behaved unethically. The field had also been hampered by different countries applying different laws to stem cell research, making international collaboration problematic, he said.Meanwhile, the use of AI in healthcare has the potential to leverage analysis of large amounts of data to improve patient outcomes, but poses ethical concerns regarding privacy, the diversity of data sources, biases and relying on non-human entities for potentially life-changing decisions.Dr. Barry Solaiman, assistant professor of law in the College of Law and Public Policy at HBKU said: 'It's very important that we bridge that gap between the professions of law and medicine, and that we understand the fundamental importance of ethicists to the advance of science. We need to consider how lawyers can help to develop laws to ensure that science advances and that it does so in ways that protect everyone involved.The event, which was co-directed by Dr. Solaiman and Dr. Thurayya Arayssi, professor of clinical medicine and senior associate dean for medical education and continuing professional development at WCM-Q, also featured other expert speakers.The event was accredited locally by the Qatar Council for Healthcare Practitioners-Accreditation Department (QCHP-AD) and internationally by the Accreditation Council for Continuing Medical Education (ACCME).

MENAFN1811201900630000ID1099287087

View original post here:
Qatar- WCM-Q explores law and ethics of stem cells and AI in medicine - MENAFN.COM

New cell therapy improves memory and stops seizures after brain injury – Drug Target Review

A recent study has shown that transplanting new inhibitory neurons may repair damaged brain circuits.

A breakthrough cell therapy to improve memory and prevent seizures in mice following traumatic brain injury (TBI) has been developed by researchers.

In the study, the research team from the University of California, US transplanted embryonic progenitor cells capable of generating inhibitory interneurons (a specific type of nerve cell that controls the activity of brain circuits) into the brains of mice with traumatic brain injury, targeting the hippocampus.

These are transplanted inhibitory neurons (green) successfully incorporated into the hippocampus of a mouse with traumatic brain injury (credit: UCI School of Medicine).

The researchers discovered that the transplanted neurons migrated into the injury where they formed new connections with the injured brain cells and thrived long term. Within a month after the treatment, the mice models showed signs of memory improvement.

The cell transplants also prevented the mice from developing epilepsy, which affected more than half of the mice who were not treated with new interneurons.

Inhibitory neurons are critically involved in many aspects of memory, and they are extremely vulnerable to dying after a brain injury, said Robert Hunt, PhD, assistant professor of anatomy and neurobiology at UCI School of Medicine who led the study. While we cannot stop interneurons from dying, it was exciting to find that we can replace them and rebuild their circuits.

To further test their observations, the team silenced the transplanted neurons with a drug, which caused the memory problems to return.

It was exciting to see the animals memory problems come back after we silenced the transplanted cells, because it showed that the new neurons really were the reason for the memory improvement, added Bingyao Zhu, a junior specialist and first author of the study.

So far, nobody has been able to convincingly create the same types of interneurons from human pluripotent stem cells, Hunt concluded. But I think were close to being able to do this.

The study was published in Nature Communications.

See more here:
New cell therapy improves memory and stops seizures after brain injury - Drug Target Review